Putnam Global Health Care Fund
Putnam Global Health Care Fund reported 45 holdings worth US$1.46B as of May 31, 2026 (Form N-PORT)
As of May 31, 2026 · Filed Jul 27, 2026
Putnam Global Health Care Fund reported 45 holdings worth US$1.46B as of May 31, 2026. Largest: Eli Lilly And Company, Johnson & Johnson and Unitedhealth Group Incorporated. Filed Jul 27, 2026 (Form N-PORT).
- Holdings
- 45
- Value as reported
- US$1.46B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Eli Lilly And Company | 174K | US$193M | 13.1% |
| Johnson & Johnson | 550K | US$124M | 8.5% |
| Unitedhealth Group Incorporated | 267K | US$102M | 6.9% |
| Abbvie Inc. | 407K | US$88.6M | 6.0% |
| Novartis Ag | 500K | US$75.2M | 5.1% |
| Merck & Company, Inc. | 602K | US$71.5M | 4.9% |
| Astrazeneca Plc | 369K | US$68.4M | 4.7% |
| Thermo Fisher Scientific Inc | 134K | US$65.9M | 4.5% |
| Intuitive Surgical, Inc. | 139K | US$59.2M | 4.0% |
| Sanofi Sa | 540K | US$47.4M | 3.2% |
| Edwards Lifesciences Corporation | 475K | US$41.1M | 2.8% |
| Roche Holding Ltd | 97,154 | US$40.9M | 2.8% |
| Cvs Health Corporation | 440K | US$40.1M | 2.7% |
| Gilead Sciences, Inc. | 286K | US$38.4M | 2.6% |
| Mckesson Corporation | 42,240 | US$31.4M | 2.1% |
| Cardinal Health, Inc. | 157K | US$31M | 2.1% |
| Vertex Pharmaceuticals Incorporated | 64,340 | US$28.8M | 2.0% |
| Novo Nordisk A/s Class B | 610K | US$27.9M | 1.9% |
| Boston Scientific Corporation | 546K | US$26.4M | 1.8% |
| Bristol-myers Squibb Company | 448K | US$25.6M | 1.8% |
| Dexcom, Inc. | 325K | US$24M | 1.6% |
| Hoya Corporation | 131K | US$22.2M | 1.5% |
| Hca Healthcare, Inc. | 45,780 | US$17.3M | 1.2% |
| Amgen Inc. | 48,160 | US$16.2M | 1.1% |
| Waters Corporation | 39,280 | US$15.1M | 1.0% |
| Argenx Se | 14,991 | US$13.5M | 0.92% |
| Gsk Plc | 509K | US$12.9M | 0.88% |
| Royalty Pharma Plc | 223K | US$12.4M | 0.85% |
| Chugai Pharmaceutical Co., Ltd. | 246K | US$12.2M | 0.83% |
| Regeneron Pharmaceuticals, Inc. | 19,538 | US$12M | 0.82% |
| Insmed Incorporated | 89,900 | US$9.61M | 0.66% |
| United Therapeutics Corporation | 15,840 | US$8.82M | 0.60% |
| Xenon Pharmaceuticals Inc. | 134K | US$7.34M | 0.50% |
| Apogee Therapeutics, Inc. | 88,000 | US$7.23M | 0.49% |
| Ascendis Pharma A/s | 31,488 | US$7.06M | 0.48% |
| Rhythm Pharmaceuticals, Inc. | 76,900 | US$6.79M | 0.46% |
| Cytokinetics, Incorporated | 54,500 | US$4.18M | 0.29% |
| Newamsterdam Pharma Company N.v. | 121K | US$4.06M | 0.28% |
| Medtronic Plc. | 0 | US$0 | 0.00% |
| Ucb S.a. | 0 | US$0 | 0.00% |
| Abbott Laboratories | 0 | US$0 | 0.00% |
| Precigen, Inc. | 0 | US$0 | 0.00% |
| Alnylam Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Vaxcyte, Inc. | 0 | US$0 | 0.00% |
| Becton, Dickinson And Company | 0 | US$0 | 0.00% |
Source
View original at SEC
Related